ACM Global Central Lab has expanded its clinical trials services with the introduction of Drug-Induced Organ Toxicity (DIOT) Monitoring, which provides trending reports for any conventional biomarkers tested, and is tailored to client requirements. It focuses on real-time detection and monitoring of elevated liver toxicity biomarkers, which signal potential drug-induced liver injury (DILI). This program follows the 2009 FDA Guidance for Industry on Drug-Induced Liver Injury. Other organ toxicity...